Abstract Information

Abstract Information

The Society for Immunotherapy of Cancer (SITC) accepted submissions of regular abstracts and late-breaking abstract applications for the 35th Anniversary Annual Meeting (SITC 2020) beginning on April 1, 2020. The deadline to submit research for a regular abstract, Young Investigator Award abstract and/or late-breaking abstract application was 5 p.m. PDT on  Aug. 26, 2020. For more information, see the 2020 Regular, Young Investigator Award and Late-Breaking Abstract Reference Guide or continue scrolling to learn more about specific abstract categories and timelines:

New Abstract Category

SITC 2020 was accepting research on COVID and Immunotherapy. Click here to learn more about abstract categories.

Abstract Information

Poster Presentation Dates

A virtual Poster Hall was available for all poster presentations. Each regular, Young Investigator Award and late-breaking abstract presenting author had the opportunity to record a brief presentation to accompany their virtual poster.

Posters were viewed beginning November 9th, 8 a.m. EST. Dedicated Virtual Poster Viewing sessions were held during the Annual Meeting. Author presence were requested during the Virtual Poster Viewing sessions to answers questions and interact with meeting attendees in real time. ePoster viewing times were scheduled for:

  • Odd numbered ePosters: Wednesday, Nov. 11 at 5:15–5:45 p.m. EST
  • Even numbered ePosters: Thursday, Nov. 12 at 4:50–5:20 p.m. EST
  • Odd numbered ePosters: Friday, Nov. 13 at 4:40–5:10 p.m. EST
  • Even numbered ePosters: Saturday, Nov. 14 at 1–1:30 p.m. EST

Regular Abstract

The time frame to submit your latest research in the cancer immunotherapy field to the 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020) for consideration as an oral abstract presentation, rapid oral abstract presentation and/or poster abstract presentation was April 1, 2020, through 5 p.m. PDT on Aug. 26, 2020.

Late-Breaking Abstract

Recognizing the unfortunate impact COVID-19 has had on the progress of cancer immunotherapy research this year, SITC leadership opened the late-breaking abstract (LBA) submission period to all submitters.

SITC no longer required a LBA application to be submitted beforehand. If you had previously submitted a LBA application, you were automatically invited to submit a full LBA during the submission period, Sept. 8–22, 2020. The LBA criteria was altered to accommodate all research regardless of whether the data was ready for submission during the regular submission period or not.

We hope this additional opportunity for abstract submission provided added assistance for all of the incredible and important work you are doing to continue to move the cancer immunotherapy field forward during this remarkably unusual year.

Late-breaking abstracts were considered for, but not limited to, oral abstract presentations during the late-breaking abstract sessions.

Young Investigator Award Abstract

Regular abstracts with primary and presenting authors that are students, postdoctoral research fellows, clinical fellows, or junior faculty with three or fewer years on staff and are current SITC members, were eligible to receive a Young Investigator Award. Young Investigator Award abstracts required a letter of recommendation as well as additional information regarding the percentage of contribution by the primary and presenting author.

Those selected for the Presidential Travel Award were invited to give an oral abstract presentation during the virtual Presidential Session.

For more information about the Young Investigator Awards, please click here.

Reasons to Submit an Abstract to SITC 2020

  • Free submission for members and nonmembers (view important submission dates)
  • Young Investigator Awards are offered in conjunction with regular abstract submission
  • All accepted abstracts will be published as a supplement in the Journal for ImmunoTherapy of Cancer (JITC), the society’s global, open access, peer-reviewed journal
  • Multiple oral presentation opportunities available
  • The opportunity to present and discuss your research with luminaries in the immunotherapy field